Seeking Alpha

Teva settles ProAir HFA patent suit

Teva Pharmaceutical Industries (TEVA +0.4%) settles its litigation against Perrigo Pharmaceutical Co. and Catalent Pharma Solutions LLC regarding four patents for Teva's ProAir HFA (albuterol sulfate) Inhalation Aerosol product. Under the terms of the settlement, Teva will provide a license to both firms to sell limited quantities of Perrigo's generic version beginning December 19, 2016 and ending June 2018. Afterward, no limits will apply.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs